Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting
Go back to Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting| (NASDAQ: RCKT) | Delayed: 3.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.46 | 52 Week High | $ | |||
| Open | $3.46 | 52 Week Low | $ | |||
| Day High | $3.46 | P/E | N/A | |||
| Day Low | $3.46 | EPS | $ | |||
| Volume | 1 | |||||
